Jade Biosciences, Inc.
Moat Score — Jade Biosciences, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | JADE101's engineered, reportedly ~755x higher APRIL-binding affinity versus the approved sibeprenlimab, plus JADE201's afucosylated, half-life-extended anti-BAFF-R design, represent real proprietary protein-engineering work, though it remains unproven in human efficacy trials. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech reliant on third-party CDMOs (WuXi Biologics, Patheon) for manufacturing, Jade has no structural cost advantage over the numerous other well-funded companies developing antibodies against the same APRIL and BAFF-R targets. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved product and an already-crowded IgA nephropathy field featuring an approved competitor (sibeprenlimab) and several late-stage rivals, Jade has no current pricing power and would need decisive clinical differentiation just to secure a commercial foothold, let alone premium pricing. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Nothing about Jade's antibody therapies becomes more valuable as more patients or physicians use them; each treatment is an independent clinical and (eventually) commercial transaction with no platform dynamic. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | With no marketed product and no patients yet dosed with JADE201, there is no installed prescriber or patient base to create switching costs; any future stickiness depends entirely on demonstrating superior results in head-to-head clinical comparisons. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | IgA nephropathy, Jade's lead indication, is already served by one approved drug and named by the company itself as having at least seven other late-stage or approved competitors, so the market is clearly not limited to only a handful of economically sustainable players. |